Minoryx Therapeutics logo

Minoryx Therapeutics S.L

Minoryx Therapeutics is a biotech company offers pharmacological chaperones, which are small molecule drugs used for the treatment of a group of rare diseases of genetic origin with a high unmet medical need.

Minoryx Therapeutics is Barcelona based company co-founded by Marc Martinell, Joan Aymam and Xavier Barril identified inhibitors for the epigenetic target LSD1 and new pharmacological chaperones.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.minoryx.com
Founded2011
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Av. Ernest Lluch 32, TCM 308302
Matar
Spain
Email
Contact Number
+34 93 544 14 66

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/minoryx-therapeutics” connections=”true” suffix=””]

Minoryx proprietary technology platform consists Pharmacological chaperones (PCT)- class of small molecule drugs which act through stabilizing unstable proteins; and Site-directed Enzyme Enhancement Therapy (SEE-Tx)- develops allosteric chaperones with natural substrate.

In Oct. 2015, Minoryx raised ‹19.4Mn in Series A funding round led by Ysios Capital, a Spanish investment fund including Kurma Partners, Roche Venture Fund, Idinvest Partners and Chiesi Ventures. Existing investors Caixa Capital Risc, the venture capital division of Çla Caixa and HealthEquity.